implantable marking device. Broad experience with the device in the United States reveals excellent results, with over 20,000 patients having undergone implantation over the past 5 years.
N
ew Zealand women have access to a robust screening mammography program. Thus, partial mastectomy with radiotherapy is standard treatment for early breast cancer. Unfortunately, for many patients worldwide, breast-conserving surgery is often (30 percent) associated with poor aesthetic outcomes. [1] [2] [3] Techniques in oncoplastic partial breast reconstruction are readily available in New Zealand. During these procedures, glandular tissue is mobilized and rearranged to fill in volume deficits in an attempt to preserve the contour of the breast. However, tunneling and tissue rearrangement can create ambiguity on imaging for radiotherapy. [4] [5] [6] [7] Historically, vascular clips have been used to mark the tumor excision site. These clips can migrate or can be confused with other clips used for hemostasis, and they do not form a threedimensional target. Typically, radiation oncologists use the seroma cavity or vascular clips for targeting; however, studies show that imprecise methods of targeting can lead to overestimation of treatment volumes, resulting in radiation exposure to nearby normal tissues, contributing to suboptimal aesthetic outcomes. [8] [9] [10] The aesthetic appearance of the breasts before and after breast cancer surgery has become increasingly important, and the surgeon's ability to reliably mark the tumor bed is critical for accurate radiotherapy and achieving good outcomes. Thus, we evaluated use of a three-dimensional marker that essentially behaves as a "mini" breast Summary: In New Zealand, oncoplastic surgery is common, but partial breast reconstruction presents challenges for radiation therapy targeting. Tissue rearrangement creates ambiguity when targeting the tumor bed, with resultant overestimation of treatment volumes. Thus, adoption of advanced methods of radiation therapy have been hindered. This pilot study describes use of a novel three-dimensional implant that provides a scaffolding for tissue ingrowth during partial breast reconstruction and delineates the tumor bed more precisely to assist radiation planning and mammographic surveillance. After informed consent, 15 women were implanted with the three-dimensional bioabsorbable implant. The device was sutured to the tumor bed during lumpectomy, and tissue flaps were mobilized and attached to the implant. Visualization of the marker and radiation treatment volumes were recorded and compared. The implant provided volume replacement and helped to maintain breast contour. Cosmetic outcomes were excellent; no device-or radiation-related complications occurred. One patient had a postoperative hematoma that resolved after percutaneous drainage; there were no postoperative infections. Three-year follow-up shows no tumor recurrences and no untoward effects. When compared to conventional radiation targeting, use of the implant showed that a greater than 50 percent reduction in treatment volume was possible in some cases. Three-year mammograms show no significant artifact, normal tissue ingrowth, and minimal fibrosis. This study describes a method of oncoplastic breast reconstruction using an implantable device that marks the site of tumor excision and provides for volume replacement with tissue ingrowth. Patients tolerated it well, and radiation therapy planning, positioning, and treatment were facilitated. 
PATIENTS AND METHODS
Fifteen patients gave consent for and underwent implantation with the BioZorb marker ( Fig. 1 ) (Focal Therapeutics, Inc., Aliso Viejo, Calif.) during partial mastectomy. The device (composed of polylactic acid and titanium clips) comes in multiple shapes and sizes (2 × 2 cm to 4 × 5 cm). The polylactic acid resorbs slowly over time (>1 year), leaving the marker clips in place. All patients had preoperative imaging, partial mastectomy, and sentinel node biopsy, and one patient required axillary dissection.
In each case, an appropriate sized tissue marker was sutured into position at the tumor excision site (Fig. 2) . Oncoplastic techniques were used to close the surgical cavities, with the surrounding margins of tissue sutured directly to the implant. As standard procedure, at least four sutures were placed and secured to the device to prevent movement.
In some cases, the marker was used to bridge the area of the defect and for additional volume replacement. Patients were referred for radiation planning 4 to 6 weeks after implantation. Optimal whole breast or partial breast radiation plans were administered in compliance with accepted clinical guidelines.
RESULTS
The marker was easily incorporated into the surgeons' routine and did not prevent or exclude any diagnostic or treatment efforts. There were no postoperative infections; nor was there evidence of inflammatory response. One patient had a small hematoma that was drained percutaneously. No devices required removal and no other complications were noted. In two patients, the implant was palpable within the breast for greater than 12 months. Excellent cosmetic outcomes were achieved in all patients with 3 years of followup, and there were no reports of pain, discomfort, deformity of the breast, or other adverse events. Figure 3 shows a patient with representative outcome at 3 years (breast cancer, right breast).
Clinical imaging clearly delineated the marker providing improved targeting, thereby assisting the radiation team in differentiating surgical tissue changes (e.g., surgical tunneling) from the site requiring treatment. Planned treatment volumes designed using the marker were significantly reduced compared with conventional methods (in some cases, reduced by >60 percent). The implantable marker assisted with radiation treatments and facilitated use of advanced methods such as accelerated partial breast irradiation, where the overall course of treatment was shortened from 6 weeks to 5 days.
DISCUSSION
Advances in breast-conservation surgery have resulted in excellent survival rates; however, poor cosmetic outcomes are common, and the options for correcting these breast deformities are limited. [11] [12] [13] [14] [15] [16] Unfortunately, too often, patients find themselves free of disease but significantly disfigured, leaving them disgruntled with their cancer Fig. 1 . BioZorb three-dimensional implantable marker. treatment. Correcting these defects often requires complex surgical interventions, and the hazard of operating on irradiated tissue brings with it additional significant risk. Thus, an implantable device that could be used for partial breast reconstruction while concomitantly marking the original tumor bed for radiation therapy and postoperative surveillance brings benefits to patient care that are most certainly innovative and worthwhile.
As seen in this initial group of patients, limiting radiation exposure to surrounding tissues also helps to improve patient outcomes by limiting fibrous scarring. The improvement in aesthetic outcomes was evident in these 15 patients, and decreased fibrosis was also noted on follow-up mammography (Fig. 4) .
In addition to improved aesthetic outcomes, recent American Society for Radiation Oncology guidelines support the use of accelerated partial breast irradiation, making shorter courses of radiation a reality for early breast cancer patients. 17 However, being able to use accelerated partial breast irradiation is dependent on limiting the volume of tissue exposed to radiation. Thus, as presented here, a consistent method for marking the excised tumor bed resulted in significantly smaller treatment volumes, thereby facilitating use of advanced methods of radiotherapy with fewer daily visits and faster completion of treatment (e.g., 5 days versus 5 weeks). These methods of irradiation also offer potential associated cost savings of up to 50 percent per patient.
CONCLUSIONS
Identifying the tumor resection site after partial mastectomy is difficult and can result in variability when prescribing radiation therapy. We assessed a novel three-dimensional, bioabsorbable marker as a framework for oncoplastic partial breast reconstruction. The implant was incorporated into our surgical practice without difficulty, and there were no complications associated with the device. Aesthetic outcomes were excellent and the device clearly marked the tumor bed, offering the radiation team additional confidence for planning and future medical needs. In this report, we describe a novel method for partial breast reconstruction using a three-dimensional Plastic and Reconstructive Surgery • January 2019
